Nonalcoholic fatty liver disease (NAFLD) is an increasingly common cause of chronic liver disease worldwide and is becoming a major public health problem. NAFLD has been recognized as a hepatic manifestation of metabolic syndrome linked with insulin resistance. Growing evidence supports that NAFLD is associated with systemic diseases such as cardiovascular disease (CVD), chronic kidney disease (CKD), type 2 diabetes, obesity, and metabolic syndrome. The majority of deaths in patients with NAFLD come from cardiovascular disease. These findings are strongly attributed to nonalcoholic steatohepatitis (NASH) rather than simple steatosis. NAFLD should be considered not only a liver specific disease but also an early mediator of systemic disease. The underlying mechanisms and pathogenesis of NAFLD with regard to other medical disorders are not yet fully understood. Further investigation is needed for future therapeutic strategies for NAFLD. This review focuses on the relationship between NAFLD and various comorbid diseases and metabolic derangement.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of liver conditions ranging from simple steatosis to nonalcoholic steatohepatitis (NASH) and advanced hepatic fibrosis [1] . The incidence of nonalcoholic fatty liver disease in adults and children is rapidly increasing due to ongoing epidemics of obesity and type 2 diabetes in Western and, more recently, in Asian populations [2] [3] [4] [5] . Prevalence estimates for NAFLD range from 17% to 33% in general populations in Western countries and a high prevalence of NAFLD has been reported especially among patients with diabetes, estimated at 34-74% [6] . NAFLD is expected to soon become the most important contributor to the need for liver transplantation [7] .
As a commonly encountered chronic liver disease [8] , NAFLD has important clinical implications because it increases all-cause mortality in patients compared to the general population of the same age and sex [9] . NAFLD has the potential to progress to cirrhosis or hepatocellular carcinoma and carries an increased risk of liver-related morbidity and mortality [10, 11] . A recent meta-analysis revealed that NAFLD diagnosed by either imaging or histology was associated with an increased risk of all-cause mortality (odds ratio
[OR] 1.57, 95% confidence intervals [CI] 1.18-2.10) [12] .
Interestingly, the main causes of mortality among patients with NAFLD were malignancy (28%) and CVD (25%).
Liver-related mortality was the third cause of death in patients with NAFLD [12] . In addition to liver-related disease, NAFLD is associated with extrahepatic manifestations.
Cumulative evidence suggests that NAFLD is linked to obesity, type 2 diabetes, dyslipidemia, and also predicts the clustering of risk factors for CVD [4, [13] [14] [15] [16] [17] . NAFLD shares com-
Journal of

Lifestyle Medicine
mon features with metabolic syndrome [18] and a growing body of evidence suggests that NAFLD is not only a surrogate marker of metabolic syndrome but also an independent risk factor for CVD, CKD and type 2 diabetes [19] . This review focuses on the recent clinical evidence supporting the association between NAFLD and extrahepatic comorbidities, including metabolic syndrome, CVD, and CKD. of patients with hyperlipidemia have ultrasonographic evidence of NAFLD [23] . A recent large community-based study of 9,162 subjects without diabetes revealed that ApoB/AI ratio was closely associated with the prevalence of NAFLD independent of obesity and other metabolic components [24] . According to a recent prospective study of 22,090 Korean men, incident hypertension was significantly higher in patients with NAFLD compared to patients without NAFLD (45% vs. 32%) and the incidence rate was correlated with the severity of ultrasonography diagnosed NAFLD [25] . Metabolic syndrome represents a chronic inflammatory state that links insulin resistance, endothelial dysfunction, and CVD, and has also been reported in NAFLD [26, 27] . Elevated C-reactive protein levels and inflammation markers have been reported in NAFLD reflecting a subclinical inflammation state related to insulin resistance that has also been related to metabolic syndrome [26] [27] [28] . All of these findings suggest that NAFLD is closely associated with metabolic syndrome and it is now widely accepted that NAFLD is a hepatic manifestation of metabolic syndrome [14, 18] .
NAFLD AND METABOLIC SYNDROME
NAFLD AND CARDIOVASCULAR DISEASE
Studies on the natural history of NAFLD have suggested that NAFLD is associated with increased risk of overall mortality and cardiovascular events compared to the general population. Importantly, CVD was a leading cause of death in subjects with NAFLD [10, 11, 29, 30] . Considering that NAFLD shares many common risk factors with CVD, it can be predicted that CVD is closely implicated in NAFLD patient mortality [31] . [48] [49] [50] [51] , and increased arterial stiffness [52] [53] [54] . A prospective study of 1,225 Chinese showed that arterial stiffness determined by measurement of brachial-ankle pulse wave velocity is more increased in NAFLD compared to subjects without NAFLD independent of cardiovascular risk factors [55] . In addition, patients with NAFLD showed impaired left ventricular diastolic dysfunction, alteration in energy metabolism, and disturbance of cardiac rhythm compared to subjects without NAFLD [56] .
In addition to macrovascular changes, NAFLD is also as- 
NAFLD AND CHRONIC KIDNEY DISEASE
Recently, several studies have reported that metabolic syndrome and insulin resistance are associated with an increased incidence of microalbuminuria and chronic kidney disease (CKD) [62] [63] [64] [65] [66] [67] . CKD and NAFLD were linked to the same cluster of cardiometabolic risk factors including metabolic syndrome and its individual components [18, [68] [69] [70] . Interrelations between NAFLD, insulin resistance, and metabolic syndrome raise the possibility that NAFLD can predict the development and progression of CKD [71] [72] [73] [74] . Due to study population heterogeneity, and differences in NAFLD diagnostic modality, NAFLD severity reporting, and CKD definition used, the reported prevalence and incidence of CKD are largely discordant.
However, most of the recent large population based and hospital based studies show that the prevalence and incidence of CKD was significantly higher in subjects with NAFLD [9, 58, 59, 67, [73] [74] [75] [76] [77] [78] [79] . According to a recent metaanalysis, NAFLD was associated with an increased preva- hypertension, and metabolic syndrome components [80] .
The prevalence of CKD ranges from 16.1% to 31.7% in subjects with liver biopsy-proven or ultrasonography diagnosed NAFLD compared to 3.7%-21.6% for control [9, [75] [76] [77] . The prevalence of CKD in patients with diabetes and comorbid NAFLD ranges from 12.7% to 54.4% compared to 4.5% to 24.2% in patients without NAFLD [58, 59, 67, 78, 79] . Two large prospective studies enrolling ultrasonography diagnosed NAFLD patients demonstrated that NAFLD was associated with the development of CKD independent of potential confounders [73, 74] . 
CONCLUSION
The prevalence of NAFLD is continuously growing worldwide and NAFLD is becoming a pandemic disease in concert with the ongoing epidemics of obesity, diabetes, and metabolic syndrome. NAFLD has a potential to progress to cirrhosis or hepatocellular carcinoma and has an increased risk of liver-related morbidity and mortality. However, morbidity and mortality is not confined to the liver. Patients with NAFLD have increased cardiovascular mortality. As a liver manifestation of metabolic syndrome, NAFLD is strongly linked to the cluster of cardiometabolic risk factors including metabolic syndrome and its individual components, and insulin resistance has an essential role in the pathogenesis of NAFLD. Growing evidence suggests that NAFLD is associated with metabolic derangement and other systemic morbidities. Furthermore, recently NAFLD has been recognized as an independent risk factor for metabolic syndrome, type 2 diabetes mellitus, CVD, and CKD and the severity of NAFLD is associated with disease manifestations.
However, there remains a lack of studies specifying the severity of NAFLD due to the invasiveness of liver biopsy, and its unsuitableness as a screening tool for a population-based epidemiological study. More detailed prospective studies are needed. NAFLD deserves particular attention given that NAFLD could be a risk factor for the development of metabolic syndrome, CVD, and CKD.
